



European
Crohn's and Colitis
Organisation

Inflammatory Bowel Diseases

Advanced ECCO:
EduCational COurse for Industry



Programme 2016-2020

www.ecco-ibd.eu

4th Advanced ECCO: EduCational COurse for Industry

Date:	Wednesday, March 6, 2019
Time:	14:00-18:00
Organisation:	ClinCom
Target audience:	Corporate Members & Non-Corporate Members
Registration:	For online registered participants only. No onsite registration.
CME accreditation:	N/A

Wednesday, March 6, 2019

Programme overview (as of February 1, 2019)

Auditorium 15, Hall A, Bella Center

14:00 - 14:05	1: Welcome & Introduction Silvio Danese, Milan, Italy
14:05 - 14:55	2: Session 1: Individualised therapy: The role of prognostic biomarkers Shomron Ben-Horin, Ramat Gan, Israel Panel discussion and interaction with the audience: Shomron Ben-Horin, Ramat Gan, Israel Silvio Danese, Milan, Italy Brihad Abhyankar, Dublin, Ireland (Theravance) Mark Ainsworth, Copenhagen, Denmark (Danish Medicines Agency) Swati Tole, San Francisco, United States (Roche)
14:55 - 15:45	3: Session 2: From phase 3 to first-line use Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France Panel discussion and interaction with the audience: Brian Feagan, London, Canada Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France Fabio Cataldi, Cambridge, United States (AbbVie) Scott Plevy, Spring House, United States (Johnson & Johnson) Elmer Schabel, Bonn, Germany (Federal Institute of Drugs and Medical Products)
15:45 - 16:15	Coffee break
16:15 - 17:05	4: Session 3: Challenges in paediatric study design Anne Griffiths, Toronto, Canada Panel discussion and interaction with the audience: Lissy de Ridder, Rotterdam, The Netherlands Anne Griffiths, Toronto, Canada Laurence D'Agay, Boudry, Switzerland (Celgene) Peter Szitanyi, Prague, Czech Republic (Charles University) William Treem, Cambridge, United States (Takeda)
17:05 - 17:55	5: Session 4: EMA recommendations for clinical trial design in IBD Mark Ainsworth, Copenhagen, Denmark (Danish Medicines Agency) Panel discussion and interaction with the audience: Mark Ainsworth, Copenhagen, Denmark John Mansfield, Newcastle Upon Tyne, United Kingdom Julián Panés, Barcelona, Spain Wulf Böcher, Ingelheim, Germany (Boehringer Ingelheim) Freddy Cornillie, Kriens, Switzerland (MSD International)
17:55 - 18:00	6: Closing remarks Krisztina Gece, Amsterdam, The Netherlands

3rd Advanced ECCO: EduCational Course for Industry

Date: February 15, 2017
Time: 14:00-18:00
Organisation: ClinCom
Target audience: Corporate & Non-Corporate Members
Registration: For registered participants only. No onsite registration
CME accreditation: n.a.

Wednesday, February 15, 2017

*Programme overview (as of January 16, 2017) –
Room 113, Level 1, CCIB*

14:00 - 14:05	1: Welcome Julián Panés, Barcelona, Spain
14:05 - 14:55	2: Session 1: Preclinical models in IBD drug development Silvio Danese, Milan, Italy Panel discussion: Gerhard Rogler, Zurich, Switzerland Andy Whitney, Foster City, United States (Gilead) Philippe Clement-Lacroix, Romainville, France (Galapagos)
14:55 - 15:45	3: Session 2: Proof of concept studies Séverine Vermeire, Leuven, Belgium Panel discussion: Stefan Schreiber, Kiel, Germany Allan Olson, San Diego, United States (Celgene) Miguel Forte, Valbonne-Sophia Antipolis, France (International Society of Cellular Therapy)
15:45 - 16:15	Coffee break
16:15 - 17:05	4: Session 3: Learning for GI from other IMIDs Bruce Sands, New York, United States Gerd-Rüdiger Burmester, Berlin, Germany Panel discussion: Chris Gasink, Malvern, United States (Janssen) Wojciech Niezychowski, Collegeville, United States (Pfizer) Elmer Schabel, Bonn, Germany (EMA)
17:05 - 17:55	5: Session 4: Treatment, strategies, trials Peter Irving, London, United Kingdom Panel discussion: John Mansfield, Newcastle upon Tyne, United Kingdom Ana Lacerda, Chicago, United States (AbbVie) Rebecca Curtis, London, United Kingdom (Takeda)
17:55 - 18:00	6: Closing remarks Silvio Danese, Milan, Italy

2nd Advanced ECCO: EduCational COurse for Industry

Date:	March 16, 2016
Time:	14:00-18:00
Organisation:	ClinCom
Target audience:	Corporate & Non-Corporate Members
Registration:	For registered participants only. No onsite registration.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room Forum, Ground level, RAI Amsterdam

14:00 - 14:05	1: Welcome Séverine Vermeire, Leuven, Belgium
14:05 - 14:55	2: Session 1: Head-to-head comparative studies: Challenges & opportunities? William Sandborn, San Diego, United States Panel discussion: Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France Anne Robinson, Highland, United States (AbbVie) Keith Usiskin, Summit, United States (Celgene)
14:55 - 15:45	3: Session 2: Patient reported outcomes measures. New data Keith Bodger, Liverpool, United Kingdom Panel discussion: Simon Travis, Oxford, United Kingdom Elmer Schabel, Bonn, Germany (EMA) Brihad Abhyankar, London, United Kingdom (Takeda)
15:45 - 16:15	Coffee break
16:15 - 17:05	4: Session 3: What challenges are faced by using cross-sectional imaging and histological endpoints in clinical trials? Julián Panés, Barcelona, Spain Vincenzo Villanacci, Brescia, Italy Panel discussion: Filip Baert, Roeselare, Belgium Gert De Hertogh, Leuven, Belgium Freddy Cornillie, Kriens, Switzerland (Merck)
17:05 - 17:55	5: Session 4: Disease-modification studies: Are we ready to start? Jean-Frédéric Colombel, New York, United States Panel discussion: Daniel Hommes, Los Angeles, United States Marc Ferrante, Leuven, Belgium Klaus Gottlieb, Rockville, United States (Synthetic Biologics)
17:55 - 18:00	6: Closing remarks Julián Panés, Barcelona, Spain